Regeneron Pharmaceuticals Inc annual operating income for fiscal TTM was $3.6 billion, an increase of 1.4% from $3.6 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $3.6B | $3.6B | $4.0B | $4.0B | $5.4B | $8.9B | $3.6B | $2.2B | $2.5B | $2.1B | $1.3B | $1.3B | $838M | $760M | $458M | ($205M) | ($97M) | ($74M) | ($90M) | ($114M) | ($107M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $643M | $880M | $1.0B | $1.1B | $592M | $990M | $1.2B | $1.1B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More REGN metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All REGN financial statements → Interactive REGN charts →
About TickerBase · Data methodology & sources